Synthorx to Present at Upcoming Investor Conferences
November 13 2019 - 7:00AM
Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology
company developing optimized therapeutics for cancer and autoimmune
disorders, today announced the Company will present at multiple
upcoming investor conferences:
Jefferies London Healthcare Conference Date:
November 20, 2019 Time: 9:20 a.m. BT (4:20 a.m. ET)Location:
London, UKStifel 2019 Healthcare Conference Date:
November 20, 2019 Time: 10:20 a.m. ET Location: New York,
NYEvercore ISI 2nd Annual HealthCONx Conference
Date: December 3, 2019 Time: 2:20 p.m. ET Location: Boston, MA |
Live webcasts of the company’s presentations will
be available at Synthorx’ investor relations website. An
archived replay will be available for 60 days following the
presentation.
To receive Synthorx’ press releases and other investor
information, please visit the Investor Relations page of the
Company’s website and register for email alerts.
About SynthorxSynthorx, Inc. is a
clinical-stage biotechnology company focused on prolonging and
improving the lives of people with cancer and autoimmune disorders.
Synthorx’ proprietary, first-of-its-kind Expanded Genetic Alphabet
platform technology expands the genetic code by adding a new DNA
base pair and is designed to create optimized biologics, referred
to as Synthorins™. A Synthorin is a protein optimized through
incorporation of novel amino acids encoded by the new DNA base pair
that enables site-specific modifications, which enhance the
pharmacological properties of these therapeutics. The company’s
lead immuno-oncology (IO) product candidate, THOR-707, a variant of
IL-2, is in development in multiple tumor types as a single agent
and in combination with an immune checkpoint inhibitor. The company
was founded based on important discoveries by Dr. Floyd Romesberg
and The Scripps Research Institute. Synthorx is headquartered in La
Jolla, Calif. For more information, visit www.synthorx.com.
Investor Relations Contacts: Enoch Kariuki,
Pharm.D.Synthorx, Inc.ekariuki@synthorx.com 858-750-4750
Christina TartagliaStern IR,
Inc.christina.tartaglia@sternir.com212-362-1200
Media Relations Contact:Lauren
FishCanale Communicationslauren@canalecomm.com619-849-5386
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Synthorx (NASDAQ:THOR)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Synthorx Inc (NASDAQ): 0 recent articles
More News Articles